result number pipelin catalyst
messag report larg in-lin quarter versu consensu provid
revenu guidanc slightli estim in-lin street
ebitda ep guidanc within prior estim continu believ
best posit amongst gener strong busi pipelin calendar
diversifi geograph mix reiter buy rate price target
result revenu middl consensu estim
north american sale declin y/i vs expect y/i declin
y/i ex-epipen fell y/i market share copaxon market
improv total rx week end new rx adjust
ep compar our/street estim gross margin
better estim year saw gener busi price
eros high-singl digit note would longer report metric
competit reason
guidanc revenu guidanc midpoint
slightli prior estim within rang prior street estim
north american revenu expect remain flat y/i european
rest world revenu expect grow high-singl digit
previous provid adj ep target modifi
rang midpoint ep guidanc compar prior/street estim
guidanc also call adj ebitda rang
midpoint compar prior/street estim
midpoint ebitda guidanc impli notion debt adj ebitda ratio
coven max permit ratio
pipelin sever signific pipelin event upcom
abroad compani still expect june approv launch gadvair also
anticip receiv fda approv biosimilar version neulasta
neulasta manag respond defici complet respons letter
feel confid underli scienc applic alreadi receiv
certain inform request agenc fda action date earli june
manag admit agenc may reinspect manufactur facil
manag expect launch product biocon current
review relat biosimilar insulin glargin pre-approv inspect
though believ quickli resolv observ anticip
launch product variou market europ follow posit chmp
recommend januari applic still review agenc eu
expect launch humira market format octob notabl launch
includ grestasi tad juli revefenacin pdufa provid
detail pipelin investor day april
model chang revenu estim move vs prior
within rang updat guidanc howev adj ep forecast remain
vs guidanc midpoint lower revenu estim off-set higher
gross margin lower opex adj ebitda estim slightli lower vs
prior maintain buy rate price target
page analyst certif import disclosur
valu use rel valuat ev/ebitda methodolog use ev/
ebitda multipl appli ebitda estim arriv
valuat valuat repres potenti upsid current level
believ premium multipl gener group specialti group
appropri given risk/benefit profil diversif outsid
pipelin contain biosimilar hard-to-manufactur complex product
risk price target includ longer expect fda approv timelin
higher expect cost failur success introduc new product market
failur penetr highli generic market obtain approv addit
competit epipen market addit gener price headwind inabl
compani pay debt manufactur inspect key plant
perform third-parti cmo clinic develop risk inabl
compani gain approv fda biosimilar product gener advair
limit intellectu properti ip protect control trade secret technolog
innov abil competitor independ develop similar better proprietari
inform techniqu disclos publicli success compet therapi
product becom avail medicar medicaid insur increas
effort manag drug spend econom weak impact unemploy commerci
insur coverag util forecast error determin mylan market
opportun risk includ compani may requir substanti addit fund
may financ futur cash need primarili public privat offer debt financ
strateg collabor may dilut stockhold compani
page analyst certif import disclosur
servic
total servic
revenu
revenu
litigation-rel
acquisition-rel charg
restructur special item
depreci amort
sale/merg expenses/adjust
interest dividend incom
equiti method loss clean energi invest
restructur special item
total servic
compani report guggenheim secur llc estim
page analyst certif import disclosur
